Finally, the stage of disease may determine the appropriate treatment as for example the levels of the CYP2E1 biomarker are high in early stages of breast cancer and gradually decline in later stages of tumor development (15,16), therefore stratifying patients according to the CYP2E1 cellular levels. The gene discussed is CYP2E1; the disease is neoplasm.